Phase 1b/2 study of pembrolizumab plus belzutifan and belzutifan alone in patients with docetaxel-treated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort J.

被引：0

作者：

Yu, Evan Y.

Joshua, Anthony M.

Shore, Neal D.

Kramer, Gero

Hu, Haixia

Poehlein, Christian Heinrich

Schloss, Charles

De Bono, Johann S.

机构：

[1] Univ Washington, Seattle, WA USA

[2] St Vincents Hosp Sydney, Sydney, NSW, Australia

[3] Carolina Urol Res Ctr, Myrtle Beach, SC USA

[4] Med Univ Vienna, Vienna, Austria

[5] Merck & Co Inc, Rahway, NJ USA

[6] Royal Marsden Hosp NHS Fdn Trust, London, England

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期

关键词：

283-183-180-5577-2829-12292; 613-615-646-3281-7408-2638; 613-135-244-3829-325; 261-492-2769; 298-145-222-184-4809-5347; 261-566-9263; 283-183-143-3231-2482; 6; 5; 4; 3; 4082; 242; 256; 38092-25779; 1;

D O I：

10.1200/JCO.2024.42.4_suppl.TPS250

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：TPS250 / TPS250

页数：1

共 50 条

[21] Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study (vol 83, pg 15, 2023)
Yu, Evan Y.
Piulats, Josep M.
Gravis, Gwenaelle
Fong, Peter C. C.
Todenhoefer, Tilman
Laguerre, Brigitte
Arranz, Jose A.
Oudard, Stephane
Massard, Christophe
Heinzelbecker, Julia
Nordquist, Luke T.
Carles, Joan
Kolinsky, Michael P.
Augustin, Marinela
Gurney, Howard
Tafreshi, Ali
Li, Xin Tong
Qiu, Ping
Poehlein, Christian H.
Schloss, Charles
de Bono, Johann S.
EUROPEAN UROLOGY, 2023, 83 (03) : E87 - E87
[22] KEYNOTE-365 cohorts E and F: Phase 1b/2 study of pembrolizumab plus lenvatinib combination therapy in patients with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC (t-NE).
Kramer, Gero
Shore, Neal D.
Joshua, Anthony M.
Li, Xin Tong
Poehlein, Christian Heinrich
Schloss, Charles
De Bono, Johann S.
Yu, Evan Y.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
[23] Pembrolizumab (pembro) combination therapies in patients with metastatic castration-resistant prostate cancer (mCRPC): Cohorts A-C of the phase Ib/II KEYNOTE-365 study
Joshua, A. M.
Gurney, H.
Retz, M.
Tafreshi, A.
Fong, P. C. C.
Shore, N. D.
Romano, E.
Augustin, M.
Piulats, J. M.
Berry, W. R.
Kolinsky, M. P.
Sridhar, S. S.
Conter, H. J.
Todenhoefer, T.
Appleman, L. J.
Wu, H.
Schloss, C.
Poehlein, C. H.
de Bono, J. S.
Yu, E. Y.
ANNALS OF ONCOLOGY, 2020, 31 : S1325 - S1325
[24] KEYNOTE-365 cohorts G and H: Phase 1b/2 study of pembrolizumab plus vibostolimab combination therapy in patients with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC (t-NE).
Shore, Neal D.
De Bono, Johann S.
Kramer, Gero
Joshua, Anthony M.
Li, Xin Tong
Poehlein, Christian Heinrich
Schloss, Charles
Yu, Evan Y.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
[25] KEYNOTE-365 Cohort A: Pembrolizumab Plus Olaparib in Docetaxel-Pretreated Patients With Metastatic Castrate-Resistant Prostate Cancer
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (04) : 14 - 15
[26] Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC): Cohort C of the phase 1b/2 KEYNOTE-365 study.
Fong, Peter C. C.
Retz, Margitta
Drakaki, Alexandra
Massard, Christophe
Berry, William R.
Romano, Emanuela
De Bono, Johann S.
Feyerabend, Susan
Appleman, Leonard Joseph
Conter, Henry Jacob
Sridhar, Srikala S.
Shore, Neal D.
Linch, Mark David
Joshua, Anthony M.
Gurney, Howard
Wu, Helen
Schloss, Charles
Poehlein, Christian Heinrich
Yu, Evan Y.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[27] Pembrolizumab (pembro) plus olaparib in patients with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): Update of KEYNOTE-365 cohort A with a minimum of 11 months of follow-up for all patients
Yu, E.
Piulats, J. M.
Gravis, G.
Fong, P. C. C.
Todenhoefer, T.
Laguerre, B.
Arranz Arija, J. A.
Oudard, S.
Massard, C.
Stoeckle, M.
Nordquist, L. T.
Carles, J.
Kolinsky, M. P.
Augustin, M.
Gurney, H.
Tafreshi, A.
Li, X. T.
Poehlein, C. H.
Schloss, C.
de Bono, J. S.
ANNALS OF ONCOLOGY, 2021, 32 : S652 - S653
[28] Keynote-365 cohort b: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC).
Massard, Christophe
Retz, Margitta
Hammerer, Peter
Quevedo, Fernando
Fong, Peter C. C.
Berry, William R.
Gurney, Howard
Piulats, Josep M.
Joshua, Anthony
Linch, Mark David
Kolinsky, Michael
Romano, Emanuela
Sridhar, Srikala S.
Conter, Henry Jacob
Augustin, Marinela
Wu, Haiyan
Schloss, Charles
Poehlein, Christian Heinrich
Yu, Evan Y.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
[29] Pembrolizumab (pembro) plus docetaxel and prednisone in patients (pts) with abiraterone acetate (abi) or enzalutamide (enza)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort B efficacy, safety and, biomarker results.
Sridhar, Srikala S.
Kolinsky, Michael Paul
Gravis, Gwenaelle
Mourey, Loic
Rodriguez, Jose Maria M. Piulats
Romano, Emanuela
Berry, William R.
Gurney, Howard
Retz, Margitta
Appleman, Leonard Joseph
Boegemann, Martin
De Bono, Johann S.
Joshua, Anthony M.
Emmenegger, Urban
Conter, Henry Jacob
Laguerre, Brigitte
Wu, Haiyan
Qiu, Ping
Schloss, Charles
Yu, Evan Y.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[30] PEMBROLIZUMAB PLUS ENZALUTAMIDE IN ABIRATERONE-PRETREATED PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: UPDATED RESULTS FROM KEYNOTE-365 COHORT C
Yu, Evan Y.
Fong, Peter
Piulats, Josep M.
Appleman, Leonard
Conter, Henry
Feyerabend, Susan
Shore, Neal
Gravis, Gwenaelle
Laguerre, Brigitte
Gurney, Howard
Retz, Margitta
Romano, Emanuela
Mourey, Loic
de Bono, Johann S.
Kam, Audrey
Emmenegger, Urban
Wu, Helen
Schloss, Charles
Poehlein, Christian
Berry, William
JOURNAL OF UROLOGY, 2020, 203 : E368 - E368

← 1 2 3 4 5 →